Pain Management Drugs Market Synopsis:
Pain Management Drugs Market Size Was Valued at USD 67.08 Billion in 2023, and is Projected to Reach USD 108.61 Billion by 2032, Growing at a CAGR of 5.5% From 2024-2032.
The Pain Management Drugs Market is a sub-sector within the pharmaceutical sector that deals with the manufacture and distribution of drugs that can be used to manage pain; it can be acute, chronic or neuropathic. This market spans across numerous drug categories, including gradual-release opioids and over-the-counter and prescription NSAIDs and other analgesics. The market in relation to the diseases is to increase for instance due to growing chronic pain conditions, raising geriatric population, and development of pain management treatment. Three of them include changing treatment methods, shift in regulatory policies and more focus on non-opioid therapies.
The market of pain management drugs has been growing constantly over the recent years due to the growing rates of chronic pain diseases including arthritis, cancer, and neurological diseases. Indeed, owing to the ageing population worldwide these conditions are becoming widespread; therefore, the need for efficient pain management solutions. Loving this market covers a broad spectrum of pharmaceutical products including opioids for moderate to severe pain, NSAIDS for mild to moderate pain and corticosteroids for severe pain. An increase in the use of non-opioid medications for management of pain is also progressing, as medications including anticonvulsants and antidepressants, may provide equal pain relief measures with less severe side effects than opioids. Drug delivery technology, for example transdermal systems and implantation technology, are demonstrating improved compliance thereby increasing efficacy of pain management therapies.
Growth drivers for pain management drugs include personalization of treatment and rising awareness about pain management across the world and across healthcare providers and patients on their own. Also, the increasing concern for the availability of the normal pain relief products especially in the developing world is playing a great role in the market expansion. However, factors like legal restraints, safety issues, and the ever-present issue of opioid crisis continue shaping the market, making manufacturers to seek for ways of developing better, safer and more effective pain relieve products. The rivalry is also changing, where manufacturers are concerned with new product development and presenting a range of differentiated product offering collaborations and acquisitions to consolidate the market indicators and the needs of the patient and provider segments.
Pain Management Drugs Market Trend Analysis:
Pain Management Drug Innovations and Trends
- The increase in the incidence of chronic pain conditions like arthritis, low back pain, neuropathic pain is the key factor fueling expansion of the market. These conditions are on the rise due to a growing elderly population and the rise in chronic disease related to lifestyle factors. With increased life expectancy and more patients adopting a more inactive lifestyle, pre valence of chronic pain has rapidly increased putting more pressure on the need to effectively manage the pain. This is so thanks to a rising concern of the advantages of pain management, which in turn is providing a boost to market growth. The opioid crisis has also provided the impetus for this shift towards other forms of analgesia regimens. This has resulted to the formulation of new pain-relieving drugs as NSAIDs, acetaminophen, corticosteroids, antidepressants as an effective pain relievin without the addictive side effects of opiates.
- In addition to this, the trend toward employing PP strategies in drugs for the management of pain is also gradually growing in the pain management drugs market. These approaches try to find optimal treatments for patients due to patient distinctive characters which would increase the efficiency and decrease the unwanted effects of the treatment. Pharmaceutical solid dosage forms like trans dermal patches and implantable systems are enhancing patient compliance and efficacy of a drug through controlled release. Government approving authorities have already started putting more emphasis on the non-opioid and effective treatments for pain management and with this trend encouraging innovation and competition is anticipated. This state of affairs probably will persist to drive the emergence of new treatment strategies with underlying emphasis on safety and effectiveness.
Growth in the Pain Management Drugs Market
- Conditions like arthritis, neuropathy and migraine are typical chronic pain diseases that have seen rising trends within the pain management drugs market. Since these conditions are increasingly being observed, the problem of pain management becomes even more relevant. The demand is further enhanced by the fact that population is aging and more people are experiencing chronic pain because of degenerative diseases associated with age. New understanding of the mechanisms of actions further propelled the development of new drugs, new analgesics, and non-opioid medicine to alleviate pain with less/harmful side effects hence making then more suitable as a choice for both health care givers and patient. All of these increase patient value and at the same time stimulate market growth.
- Furthermore, the changing trend in the Pain Management Drugs market due to the increasing focus towards personalized medicine is a good sign for this market. Healthcare providers will thus have to provide targeted treatment solutions that would respond adequately to the differing forms of the pains experienced by patients. This approach not only benefits the patient through improving the likelihood for better value cure, but also increases the likelihood of patients being satisfied and compliant with organization laid down health rules. The presence of digital health technologies including; mobile apps, wearable devices for pain management contribute to the growth of the market as they provide real time information for better decision making in pain management.
Pain Management Drugs Market Segment Analysis:
Pain Management Drugs Market is Segmented on the basis of Drug class, Indication Type, Pain Type, Distribution Channel, and Region.
By Drug class, NSAIDS segment is expected to dominate the market during the forecast period
- Nonsteroidal anti-inflammatory drugs or NSAIDs are one of the major classes of the pain management products that work through the reduction of inflammation of the tissues in pain affected areas and thereby relief of pain. NSAIDs group is constituted commonly used drugs such as, ibuprofen, aspirin, naproxen among others. They are used for the management of conditions such as arthritis, muscle injuries and menstrual cramps, with no interference of narcotics. Through IT helping to reduce the pain and improve the range of movement of patients, it also exhibits anti-inflammatory actions. They should be easily obtainable from the retail pharmacies and over the counter through the internet therefore can be easily used by patients, without any prescription from doctors.
- One of the main benefite of NSAIDs is that they are effective in moderate pain, like pain that occurs from a mild injury or simple surgery. The way they work is by blocking the synthesis of some chemicals that induce inflammation and pain as prostaglandins. This makes it fit to be used in both the short term and the long-term management of pain. Due to the easy availability, NSAIDs are prescribed for a wide variety of pain ailments and are effective and rapidly acting for the majority of patients.
By Distribution Channel, Hospital pharmacies segment expected to held the largest share
- One of the aspects that involve setting up a hospital pharmacy is that it ensures that medications for pain management are well offered, given the high level of detail that is usually taken when handling such products. They are especially designed for managing such quantities of controlled substances as opioids to avoid misuse while being administered by a professional pharmacist. This is important in handling strong opioids where there is likelihood of the drug getting into the wrong hand and thereby leading to harm of the patient. Inpatient and outpatient hospital pharmacies also provide counseling to patients about use of their prescription as well as ways to address side effects and other changes that can be made to support pain control.
- Apart from giving out drugs, the hospital pharmacy entails follow up since some patients have special needs in regards to pain management for instance, cancer affected patients or those who underwent surgery. This follow-up encompasses follow up of the patient’s progress, modification of dosage in the supplied medications and evaluating compliance to treatment. Being involved in the patient’s care on a continuous basis the hospital pharmacists keep patients safe and ensured that their pain is well managed.
Pain Management Drugs Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America have a large market for pain management drugs as explained below. Moderate level of overall health care expenditure in the region makes it possible for all to afford better or premium medical support systems of required pain management treatments. Most importantly, the US dominates the global consumption of hydrocodone because, for instance, opioids are frequently prescribed, and that Americans take pain seriously. This is well enhanced by having a developed health care system that recognizes pain management interventions such as drugs and other intercessions. Also, the opportunities for the development of the American market for pain management drugs are supported by the availability of key pharmaceutical producers and wide research and development activities.
- In the years ahead, the Canadian market will be important in a shift toward non-opioid pain management drugs and a greater emphasis on disease prevention. The policies and programs implemented by the governments to curb or lessen opioid use are making more therapies such as NSAIDs and physical, psychological therapies more popular among clinicians.” The Canadian pain management market could therefore be boosted by the growth of the population aging who are likely to require the service as they grow old. Moreover, the relations between health care organizations and pharmaceutical firms in Canada are improving the availability of modern pain management solutions and, therefore, the competitive environment of the market.
Active Key Players in the Pain Management Drugs Market
- Abbott Laboratories
- Eli Lilly and Company
- ENDO HEALTH SOLUTIONS INC. (ENDO INTERNATIONAL PLC.)
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co., Inc.
- Mylan N.V.
- Novartis AG Pfizer, Inc.
- Purdue Pharma L.P.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Other Active Players.
|
Pain Management Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 67.08 Billion |
|
Forecast Period 2024-32 CAGR: |
5.5% |
Market Size in 2032: |
USD 108.61Billion |
|
Segments Covered:
|
By Drug class |
|
|
|
By Indication Type |
|
||
|
By Pain Type |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Pain Management Drugs Market by Drug class
4.1 Pain Management Drugs Market Snapshot and Growth Engine
4.2 Pain Management Drugs Market Overview
4.3 NSAIDS
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 NSAIDS: Geographic Segmentation Analysis
4.4 Anesthetics
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Anesthetics: Geographic Segmentation Analysis
4.5 Anticonvulsants
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Anticonvulsants: Geographic Segmentation Analysis
4.6 Antimigraine drugs
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Antimigraine drugs: Geographic Segmentation Analysis
4.7 Antidepressant drugs
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Antidepressant drugs: Geographic Segmentation Analysis
4.8 Opioids
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Opioids: Geographic Segmentation Analysis
4.9 Non-narcotic analgesics and Other drugs
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Non-narcotic analgesics and Other drugs: Geographic Segmentation Analysis
Chapter 5: Pain Management Drugs Market by Indication Type,
5.1 Pain Management Drugs Market Snapshot and Growth Engine
5.2 Pain Management Drugs Market Overview
5.3 Arthritic pain
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Arthritic pain: Geographic Segmentation Analysis
5.4 Neuropathic pain
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Neuropathic pain: Geographic Segmentation Analysis
5.5 Cancer pain
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Cancer pain: Geographic Segmentation Analysis
5.6 Chronic back pain
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Chronic back pain: Geographic Segmentation Analysis
5.7 post-operative pain
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 post-operative pain: Geographic Segmentation Analysis
5.8 Migraine
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Migraine: Geographic Segmentation Analysis
5.9 Fibromyalgia
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Fibromyalgia: Geographic Segmentation Analysis
5.10 Bone fracture
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 Bone fracture: Geographic Segmentation Analysis
5.11 Muscle sprain/strain
5.11.1 Introduction and Market Overview
5.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.11.3 Key Market Trends, Growth Factors and Opportunities
5.11.4 Muscle sprain/strain: Geographic Segmentation Analysis
5.12 Acute appendicitis and other indications
5.12.1 Introduction and Market Overview
5.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.12.3 Key Market Trends, Growth Factors and Opportunities
5.12.4 Acute appendicitis and other indications: Geographic Segmentation Analysis
Chapter 6: Pain Management Drugs Market by Pain Type
6.1 Pain Management Drugs Market Snapshot and Growth Engine
6.2 Pain Management Drugs Market Overview
6.3 Chronic type and Acute type
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Chronic type and Acute type: Geographic Segmentation Analysis
Chapter 7: Pain Management Drugs Market by Distribution Channel,
7.1 Pain Management Drugs Market Snapshot and Growth Engine
7.2 Pain Management Drugs Market Overview
7.3 Hospital pharmacies
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Hospital pharmacies: Geographic Segmentation Analysis
7.4 Retail pharmacies and Online pharmacies
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Retail pharmacies and Online pharmacies: Geographic Segmentation Analysis
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Benchmarking
8.1.2 Pain Management Drugs Market Share by Manufacturer (2023)
8.1.3 Industry BCG Matrix
8.1.4 Heat Map Analysis
8.1.5 Mergers and Acquisitions
8.2 ENDO HEALTH SOLUTIONS INC. (ENDO INTERNATIONAL PLC.)
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Role of the Company in the Market
8.2.5 Sustainability and Social Responsibility
8.2.6 Operating Business Segments
8.2.7 Product Portfolio
8.2.8 Business Performance
8.2.9 Key Strategic Moves and Recent Developments
8.2.10 SWOT Analysis
8.3 MERCK & CO. INC.
8.4 NOVARTIS AG PFIZER INC.
8.5 SANOFI S.A.
8.6 MYLAN N.V.
8.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8 ELI LILLY AND COMPANY
8.9 ABBOTT LABORATORIES
8.10 PURDUE PHARMA L.P.
8.11 GLAXOSMITHKLINE PLC.
8.12 JOHNSON & JOHNSON
8.13 F. HOFFMANN LA ROCHE LTD
8.14 OTHER ACTIVE PLAYERS
Chapter 9: Global Pain Management Drugs Market By Region
9.1 Overview
9.2. North America Pain Management Drugs Market
9.2.1 Key Market Trends, Growth Factors and Opportunities
9.2.2 Top Key Companies
9.2.3 Historic and Forecasted Market Size by Segments
9.2.4 Historic and Forecasted Market Size By Drug class
9.2.4.1 NSAIDS
9.2.4.2 Anesthetics
9.2.4.3 Anticonvulsants
9.2.4.4 Antimigraine drugs
9.2.4.5 Antidepressant drugs
9.2.4.6 Opioids
9.2.4.7 Non-narcotic analgesics and Other drugs
9.2.5 Historic and Forecasted Market Size By Indication Type,
9.2.5.1 Arthritic pain
9.2.5.2 Neuropathic pain
9.2.5.3 Cancer pain
9.2.5.4 Chronic back pain
9.2.5.5 post-operative pain
9.2.5.6 Migraine
9.2.5.7 Fibromyalgia
9.2.5.8 Bone fracture
9.2.5.9 Muscle sprain/strain
9.2.5.10 Acute appendicitis and other indications
9.2.6 Historic and Forecasted Market Size By Pain Type
9.2.6.1 Chronic type and Acute type
9.2.7 Historic and Forecasted Market Size By Distribution Channel,
9.2.7.1 Hospital pharmacies
9.2.7.2 Retail pharmacies and Online pharmacies
9.2.8 Historic and Forecast Market Size by Country
9.2.8.1 US
9.2.8.2 Canada
9.2.8.3 Mexico
9.3. Eastern Europe Pain Management Drugs Market
9.3.1 Key Market Trends, Growth Factors and Opportunities
9.3.2 Top Key Companies
9.3.3 Historic and Forecasted Market Size by Segments
9.3.4 Historic and Forecasted Market Size By Drug class
9.3.4.1 NSAIDS
9.3.4.2 Anesthetics
9.3.4.3 Anticonvulsants
9.3.4.4 Antimigraine drugs
9.3.4.5 Antidepressant drugs
9.3.4.6 Opioids
9.3.4.7 Non-narcotic analgesics and Other drugs
9.3.5 Historic and Forecasted Market Size By Indication Type,
9.3.5.1 Arthritic pain
9.3.5.2 Neuropathic pain
9.3.5.3 Cancer pain
9.3.5.4 Chronic back pain
9.3.5.5 post-operative pain
9.3.5.6 Migraine
9.3.5.7 Fibromyalgia
9.3.5.8 Bone fracture
9.3.5.9 Muscle sprain/strain
9.3.5.10 Acute appendicitis and other indications
9.3.6 Historic and Forecasted Market Size By Pain Type
9.3.6.1 Chronic type and Acute type
9.3.7 Historic and Forecasted Market Size By Distribution Channel,
9.3.7.1 Hospital pharmacies
9.3.7.2 Retail pharmacies and Online pharmacies
9.3.8 Historic and Forecast Market Size by Country
9.3.8.1 Bulgaria
9.3.8.2 The Czech Republic
9.3.8.3 Hungary
9.3.8.4 Poland
9.3.8.5 Romania
9.3.8.6 Rest of Eastern Europe
9.4. Western Europe Pain Management Drugs Market
9.4.1 Key Market Trends, Growth Factors and Opportunities
9.4.2 Top Key Companies
9.4.3 Historic and Forecasted Market Size by Segments
9.4.4 Historic and Forecasted Market Size By Drug class
9.4.4.1 NSAIDS
9.4.4.2 Anesthetics
9.4.4.3 Anticonvulsants
9.4.4.4 Antimigraine drugs
9.4.4.5 Antidepressant drugs
9.4.4.6 Opioids
9.4.4.7 Non-narcotic analgesics and Other drugs
9.4.5 Historic and Forecasted Market Size By Indication Type,
9.4.5.1 Arthritic pain
9.4.5.2 Neuropathic pain
9.4.5.3 Cancer pain
9.4.5.4 Chronic back pain
9.4.5.5 post-operative pain
9.4.5.6 Migraine
9.4.5.7 Fibromyalgia
9.4.5.8 Bone fracture
9.4.5.9 Muscle sprain/strain
9.4.5.10 Acute appendicitis and other indications
9.4.6 Historic and Forecasted Market Size By Pain Type
9.4.6.1 Chronic type and Acute type
9.4.7 Historic and Forecasted Market Size By Distribution Channel,
9.4.7.1 Hospital pharmacies
9.4.7.2 Retail pharmacies and Online pharmacies
9.4.8 Historic and Forecast Market Size by Country
9.4.8.1 Germany
9.4.8.2 UK
9.4.8.3 France
9.4.8.4 Netherlands
9.4.8.5 Italy
9.4.8.6 Russia
9.4.8.7 Spain
9.4.8.8 Rest of Western Europe
9.5. Asia Pacific Pain Management Drugs Market
9.5.1 Key Market Trends, Growth Factors and Opportunities
9.5.2 Top Key Companies
9.5.3 Historic and Forecasted Market Size by Segments
9.5.4 Historic and Forecasted Market Size By Drug class
9.5.4.1 NSAIDS
9.5.4.2 Anesthetics
9.5.4.3 Anticonvulsants
9.5.4.4 Antimigraine drugs
9.5.4.5 Antidepressant drugs
9.5.4.6 Opioids
9.5.4.7 Non-narcotic analgesics and Other drugs
9.5.5 Historic and Forecasted Market Size By Indication Type,
9.5.5.1 Arthritic pain
9.5.5.2 Neuropathic pain
9.5.5.3 Cancer pain
9.5.5.4 Chronic back pain
9.5.5.5 post-operative pain
9.5.5.6 Migraine
9.5.5.7 Fibromyalgia
9.5.5.8 Bone fracture
9.5.5.9 Muscle sprain/strain
9.5.5.10 Acute appendicitis and other indications
9.5.6 Historic and Forecasted Market Size By Pain Type
9.5.6.1 Chronic type and Acute type
9.5.7 Historic and Forecasted Market Size By Distribution Channel,
9.5.7.1 Hospital pharmacies
9.5.7.2 Retail pharmacies and Online pharmacies
9.5.8 Historic and Forecast Market Size by Country
9.5.8.1 China
9.5.8.2 India
9.5.8.3 Japan
9.5.8.4 South Korea
9.5.8.5 Malaysia
9.5.8.6 Thailand
9.5.8.7 Vietnam
9.5.8.8 The Philippines
9.5.8.9 Australia
9.5.8.10 New Zealand
9.5.8.11 Rest of APAC
9.6. Middle East & Africa Pain Management Drugs Market
9.6.1 Key Market Trends, Growth Factors and Opportunities
9.6.2 Top Key Companies
9.6.3 Historic and Forecasted Market Size by Segments
9.6.4 Historic and Forecasted Market Size By Drug class
9.6.4.1 NSAIDS
9.6.4.2 Anesthetics
9.6.4.3 Anticonvulsants
9.6.4.4 Antimigraine drugs
9.6.4.5 Antidepressant drugs
9.6.4.6 Opioids
9.6.4.7 Non-narcotic analgesics and Other drugs
9.6.5 Historic and Forecasted Market Size By Indication Type,
9.6.5.1 Arthritic pain
9.6.5.2 Neuropathic pain
9.6.5.3 Cancer pain
9.6.5.4 Chronic back pain
9.6.5.5 post-operative pain
9.6.5.6 Migraine
9.6.5.7 Fibromyalgia
9.6.5.8 Bone fracture
9.6.5.9 Muscle sprain/strain
9.6.5.10 Acute appendicitis and other indications
9.6.6 Historic and Forecasted Market Size By Pain Type
9.6.6.1 Chronic type and Acute type
9.6.7 Historic and Forecasted Market Size By Distribution Channel,
9.6.7.1 Hospital pharmacies
9.6.7.2 Retail pharmacies and Online pharmacies
9.6.8 Historic and Forecast Market Size by Country
9.6.8.1 Turkey
9.6.8.2 Bahrain
9.6.8.3 Kuwait
9.6.8.4 Saudi Arabia
9.6.8.5 Qatar
9.6.8.6 UAE
9.6.8.7 Israel
9.6.8.8 South Africa
9.7. South America Pain Management Drugs Market
9.7.1 Key Market Trends, Growth Factors and Opportunities
9.7.2 Top Key Companies
9.7.3 Historic and Forecasted Market Size by Segments
9.7.4 Historic and Forecasted Market Size By Drug class
9.7.4.1 NSAIDS
9.7.4.2 Anesthetics
9.7.4.3 Anticonvulsants
9.7.4.4 Antimigraine drugs
9.7.4.5 Antidepressant drugs
9.7.4.6 Opioids
9.7.4.7 Non-narcotic analgesics and Other drugs
9.7.5 Historic and Forecasted Market Size By Indication Type,
9.7.5.1 Arthritic pain
9.7.5.2 Neuropathic pain
9.7.5.3 Cancer pain
9.7.5.4 Chronic back pain
9.7.5.5 post-operative pain
9.7.5.6 Migraine
9.7.5.7 Fibromyalgia
9.7.5.8 Bone fracture
9.7.5.9 Muscle sprain/strain
9.7.5.10 Acute appendicitis and other indications
9.7.6 Historic and Forecasted Market Size By Pain Type
9.7.6.1 Chronic type and Acute type
9.7.7 Historic and Forecasted Market Size By Distribution Channel,
9.7.7.1 Hospital pharmacies
9.7.7.2 Retail pharmacies and Online pharmacies
9.7.8 Historic and Forecast Market Size by Country
9.7.8.1 Brazil
9.7.8.2 Argentina
9.7.8.3 Rest of SA
Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies
Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research
|
Pain Management Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 67.08 Billion |
|
Forecast Period 2024-32 CAGR: |
5.5% |
Market Size in 2032: |
USD 108.61Billion |
|
Segments Covered:
|
By Drug class |
|
|
|
By Indication Type |
|
||
|
By Pain Type |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
